UBE2O and breast cancer: To further explore whether mTORC1 pathway activation was critical for the oncogenic activity of UBE2O in BC cells, MCF-7NC/MCF-7OE-UBE2O cells were treated with rapamycin, an endogenous mTOR inhibitor.